CMS to delay part of controversial Medicaid drug rule

(By Alia Paavola for Becker’s Hospital Review)

CMS plans to delay the start date for a rule that would require drugmakers to report the discounts they offer patients when calculating the “best price” for drugs in the Medicaid rebate program, according to a proposed rule submitted this week.  Continue reading the article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org